摩根士丹利因扩大HCP平台市场而升级Doximity

2025-12-16 00:24

Morgan Stanley upgraded Doximity to overweight from equal-weight saying that platforms geared toward health care providers are seeing growth in targeted marketing.
The firm boosted its target price to $65 from $62 ( upside based on Dec. 12 close).
Analyst Craig Hettenbach said that with shares experiencing a 30% correction since its latest earnings report on Nov. 6, the stock is now at an attractive entry point. He added that Doximity is down 18% year to date even though 2025 revenue and EBITDA estimates were revised higher by, respectively, 9% and 21%, since the beginning of the year.
"Doximity has consistently expanded a suite of tools, deepening its integration into clinicians’ daily workflows, resulting in increased engagement and higher monetization," Hettenbach wrote.
He added that an "expanding toolkit of workflow solutions not only enhances the stickiness of the platform but also provides levers to monetize the user base."
Hettenbach noted that increasing restrictions on direct-to-consumer drug advertising could lead to a shift in ad dollars to platform such as Doximity.

More on Doximity